These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 22938399)
1. Outcome of febrile neutropenic patients on granulocyte colony stimulating factor in a tertiary care hospital. Osmani AH; Ansari TZ; Masood N; Ahmed B Asian Pac J Cancer Prev; 2012; 13(6):2523-6. PubMed ID: 22938399 [TBL] [Abstract][Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560 [TBL] [Abstract][Full Text] [Related]
3. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839 [TBL] [Abstract][Full Text] [Related]
4. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696 [TBL] [Abstract][Full Text] [Related]
5. [Prevention and treatment of febrile neutropenia]. Montemurro F; Gallicchio M; Aglietta M Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724 [TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. Ozkaynak MF; Krailo M; Chen Z; Feusner J Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544 [TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861 [TBL] [Abstract][Full Text] [Related]
8. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Wong SF; Chan HO Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284 [TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia. Chan A; Wong QX; Ali MK; Wong M; Hsu LY Support Care Cancer; 2014 Apr; 22(4):1105-12. PubMed ID: 24317848 [TBL] [Abstract][Full Text] [Related]
10. Lack of benefit of granulocyte macrophage or granulocyte colony stimulating factor in patients with febrile neutropenia. Siddiqui T; Burney IA; Kakepoto GN; Khurshid M; Salam A; Smego RA J Pak Med Assoc; 2002 May; 52(5):206-10. PubMed ID: 12174492 [TBL] [Abstract][Full Text] [Related]
11. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Maher DW; Lieschke GJ; Green M; Bishop J; Stuart-Harris R; Wolf M; Sheridan WP; Kefford RF; Cebon J; Olver I; McKendrick J; Toner G; Bradstock K; Lieschke M; Cruickshank S; Tomita DK; Hoffman EW; Fox RM; Morstyn G Ann Intern Med; 1994 Oct; 121(7):492-501. PubMed ID: 7520676 [TBL] [Abstract][Full Text] [Related]
13. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol. Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677 [TBL] [Abstract][Full Text] [Related]
14. The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy. Halalsheh OM; Al Zu'bi YO; Al Sharie AH; Wafai FH; Alabdallah N; AlSeidi J; Hussein AA; Daoud MN; Malkawi AA; Alomari AO; Alshari O Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363465 [No Abstract] [Full Text] [Related]
15. Granulocyte-colony stimulating factor for the prevention of chemotherapy-induced febrile neutropenia in the adult cancer patient population of Southern Israel. Gilad J; Riesenberg K; Mermershtain W; Borer A; Porath A; Schlaeffer F Support Care Cancer; 1999 Jul; 7(4):260-4. PubMed ID: 10423052 [TBL] [Abstract][Full Text] [Related]
16. Colony stimulating factors for chemotherapy induced febrile neutropenia. Clark OA; Lyman G; Castro AA; Clark LG; Djulbegovic B Cochrane Database Syst Rev; 2003; (3):CD003039. PubMed ID: 12917942 [TBL] [Abstract][Full Text] [Related]
17. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Vellenga E; Uyl-de Groot CA; de Wit R; Keizer HJ; Löwenberg B; ten Haaft MA; de Witte TJ; Verhagen CA; Stoter GJ; Rutten FF; Mulder NH; Smid WM; de Vries EG J Clin Oncol; 1996 Feb; 14(2):619-27. PubMed ID: 8636779 [TBL] [Abstract][Full Text] [Related]
18. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780 [TBL] [Abstract][Full Text] [Related]
19. Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin. Meza LA; Green MD; Hackett JR; Neumann TA; Holmes FA Pharmacotherapy; 2003 Nov; 23(11):1424-31. PubMed ID: 14620389 [TBL] [Abstract][Full Text] [Related]
20. Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patients. Chernobelski P; Lavrenkov K; Rimar D; Riesenberg K; Schlaeffer F; Ariad S; Mermershtain W Chemotherapy; 2006; 52(4):185-9. PubMed ID: 16675902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]